Einzeltreffer — DigiBib

Objective: The aim of this study was to predict response to neoadjuvant chemotherapy (NAC) in patients with locally advanced hypopharyngeal cancer by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Methods: A retrospective study enrolled 46 diagnosed locally advanced hypopharyngeal cancer. DCE-MRI were performed prior to and after two cycles of NAC. The volume transfer constant (K trans ), extracellular extravascular volume fraction (V e ), and plasma volume fraction (K ep ) were computed from primary tumors. DCE-MRI parameters were used to measure tumor response according to the Response Evaluation Criteria in Solid Tumors criteria (RECIST). Results： After 2 NAC cycles, 30 out of 46 patients were categorized into the responder group, whereas the other 16 were categorized into non-responder group. Compared with the pretreatment value, the post-treatment K trans and K ep was significantly lower ( P < 0.05), but no significant change in V e ( P > 0.05). Compared with non-responders, a notably higher pretreatment K trans , K ep , lower post-treatment K trans , higher ΔK trans and ΔK ep were observed in responders (all P < 0.05). While the pretreatment V e , post-treatment V e , and ΔV e did not differ significantly ( P> 0.05) between the two groups. The receiver operating characteristic curve analysis revealed that pretreatment K trans of 0.202/min is the most optimal cut-off in predicting response to chemotherapy, resulting in an AUC of 0.837 and corresponding sensitivity and specificity of 76.7%, and 81.1%, respectively. Conclusion: DCE-MRI especially pretreatment K trans can potentially predict the treatment response to neoadjuvant chemotherapy for hypopharyngeal cancer. Advances in knowledge: Few studies of DCE-MRI on hypopharyngeal cancer treated with chemoradiation reported. The results demonstrate that DCE-MRI especially pretreatment K trans may be more potential value in predicting the treatment response to neoadjuvant chemotherapy for hypopharyngeal cancer.

Titel:	Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for pretreatment prediction of neoadjuvant chemotherapy response in locally advanced hypopharyngeal cancer.
Autor/in / Beteiligte Person:	Guo, W ; Zhang, Y ; Luo, D ; Yuan, H
Link:	Full Text Finder (Volltext)
Zeitschrift:	The British journal of radiology, Jg. 93 (2020-11-01), Heft 1115, S. 20200751
Veröffentlichung:	January 2024- : [Oxford] : Oxford University Press ; <i>Original Publication</i>: London, British Institute of Radiology., 2020
Medientyp:	academicJournal
ISSN:	1748-880X (electronic)
DOI:	10.1259/bjr.20200751
Schlagwort:	Aged Antineoplastic Combined Chemotherapy Protocols administration & dosage Carcinoma, Squamous Cell blood supply Carcinoma, Squamous Cell diagnostic imaging Carcinoma, Squamous Cell drug therapy Chemotherapy, Adjuvant methods Cisplatin administration & dosage Female Humans Hypopharyngeal Neoplasms blood supply Male Middle Aged Paclitaxel administration & dosage ROC Curve Response Evaluation Criteria in Solid Tumors Retrospective Studies Treatment Outcome Contrast Media Hypopharyngeal Neoplasms diagnostic imaging Hypopharyngeal Neoplasms drug therapy Image Enhancement methods Magnetic Resonance Imaging methods Neoadjuvant Therapy methods
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Br J Radiol] 2020 Nov 01; Vol. 93 (1115), pp. 20200751. <i>Date of Electronic Publication: </i>2020 Sep 11. MeSH Terms: Contrast Media* ; Hypopharyngeal Neoplasms / diagnostic imaging ; Hypopharyngeal Neoplasms / drug therapy ; Image Enhancement / methods ; Magnetic Resonance Imaging / methods ; Neoadjuvant Therapy / *methods ; Aged ; Antineoplastic Combined Chemotherapy Protocols / administration & dosage ; Carcinoma, Squamous Cell / blood supply ; Carcinoma, Squamous Cell / diagnostic imaging ; Carcinoma, Squamous Cell / drug therapy ; Chemotherapy, Adjuvant / methods ; Cisplatin / administration & dosage ; Female ; Humans ; Hypopharyngeal Neoplasms / blood supply ; Male ; Middle Aged ; Paclitaxel / administration & dosage ; ROC Curve ; Response Evaluation Criteria in Solid Tumors ; Retrospective Studies ; Treatment Outcome References: PLoS One. 2015 Aug 13;10(8):e0134749. (PMID: 26270054) ; AJNR Am J Neuroradiol. 2007 Feb;28(2):328-34. (PMID: 17297007) ; PLoS One. 2018 Mar 28;13(3):e0194841. (PMID: 29590180) ; Exp Biol Med (Maywood). 2011 Apr 1;236(4):375-89. (PMID: 21427235) ; Eur J Radiol. 2012 Nov;81(11):3313-8. (PMID: 22608396) ; N Engl J Med. 2003 Nov 27;349(22):2091-8. (PMID: 14645636) ; Eur Radiol. 2014 Jan;24(1):223-31. (PMID: 24013848) ; Semin Radiat Oncol. 2004 Jul;14(3):198-206. (PMID: 15254862) ; Angiogenesis. 2008;11(2):109-19. (PMID: 18293091) ; Oral Oncol. 2014 Oct;50(10):963-70. (PMID: 25116700) ; J Magn Reson Imaging. 1999 Sep;10(3):223-32. (PMID: 10508281) ; Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774) ; Lancet Oncol. 2013 Mar;14(3):257-64. (PMID: 23414589) ; Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1176-83. (PMID: 21546171) ; AJNR Am J Neuroradiol. 2010 Feb;31(2):262-8. (PMID: 19797785) ; Eur Radiol. 2016 Nov;26(11):4162-4172. (PMID: 26911889) ; Head Neck. 2012 Feb;34(2):270-81. (PMID: 22228621) ; AJNR Am J Neuroradiol. 2011 Apr;32(4):778-84. (PMID: 21349969) ; AJR Am J Roentgenol. 2013 Jan;200(1):35-43. (PMID: 23255739) ; Medicine (Baltimore). 2019 Aug;98(33):e16608. (PMID: 31415354) ; Eur Radiol. 2012 Apr;22(4):821-31. (PMID: 22101743) ; Magn Reson Imaging. 2014 Dec;32(10):1206-13. (PMID: 25131628) ; PLoS One. 2013 Aug 07;8(8):e72230. (PMID: 23951300) ; J Clin Oncol. 2014 Sep 1;32(25):2735-43. (PMID: 25049329) ; Cancer. 2012 Aug 1;118(15):3776-85. (PMID: 22180392) ; Ann Surg Oncol. 2010 Jun;17(6):1471-4. (PMID: 20180029) ; Radiology. 2003 Feb;226(2):345-54. (PMID: 12563124) ; Laryngoscope. 2014 Sep;124(9):2064-9. (PMID: 25295351) ; Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):299-307. (PMID: 21236594) ; Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):766-73. (PMID: 19019563) ; Acta Radiol. 2015 Mar;56(3):294-303. (PMID: 24609871) ; Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14266-71. (PMID: 23940372) Substance Nomenclature: 0 (Contrast Media) ; P88XT4IS4D (Paclitaxel) ; Q20Q21Q62J (Cisplatin) Entry Date(s): Date Created: 20200911 Date Completed: 20201029 Latest Revision: 20211102 Update Code: 20240513 PubMed Central ID: PMC8519657

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) for pretreatment prediction of neoadjuvant chemotherapy response in locally advanced hypopharyngeal cancer.